Abstract CD40 ligand (CD40L) acts as an immune modulator in activated T cells, and mutations in the extracellular domain are associated to X-linked hyper IgM syndrome. A role for platelet CD40L in mediating thrombotic and inflammatory processes in atherosclerosis has also been reported. Using the Cre/loxP recombination technology we generated four knockout lines of mice with deletion of the Cd40lg gene restricted to the hematopoietic system. Mouse lines with expression of Cre recombinase driven by the Tie2, Vav1, or CD4 promoters showed in vivo ablation of CD40L in leukocytes and platelets. In contrast, in mice with Cre expression driven by the megakaryocyte lineage-restricted Pf4 promoter, abolition of CD40L expression was observed in megakaryocytes cultured in vitro, but not in circulating platelets. Characterization of these animals revealed reduced in vivo thrombogenesis and defective activation of washed CD40L-deficient platelets, suggesting that membrane-bound CD40L is involved in the control of haemostasis acting as a platelet co-activator. In addition, we report the practically absence of CD40L in mouse and human endothelial cells, as well as the detection of an exon 3-deleted CD40L transcript in both platelets and leukocytes of mouse and human origin. Finally, compared with their corresponding littermate floxed controls, Cre? mice carrying CD40-deficient leukocytes did not exhibit increased IgM levels, and reduction of IgA and IgG levels was statistically significant only in Tie2-Cre? mice, suggesting that expression of CD40L in an earlier developmental step may be determinant in the regulation of the class switch recombination process.
Introduction
The ligand of the CD40 receptor, CD40L, is a type II membrane glycoprotein of the tumor necrosis factor ligand (TNFL) superfamily composed of 215 amino acids distributed in three functional domains: a 22 AA intracellular domain, a 24 AA transmembrane domain, and a cysteine-rich extracellular domain containing 215 AA. The sandwich structure of the TNFL Electronic supplementary material The online version of this article (doi:10.1007/s11248-013-9743-2) contains supplementary material, which is available to authorized users.
homology domain in the extracellular region allows the typical trimeric organization of the members of this family of proteins (Shimadzu et al. 1995) . Besides the complete 39 kDa CD40L molecule bound to the plasma membrane, there is a soluble 18 kDa form (sCD40L) that can associate with the complete form of the protein in biologically active heterotrimeric complexes (Graf et al. 1995) .
The role of CD40L as an immune modulator is well known. It has been implicated in several immune events including B cell proliferation, differentiation, isotype switching, regulation of stimulatory molecules, activation of antigen presenting cells and modulation of T cell priming (Elgueta et al. 2009 ). CD40L is also involved in haematopoietic development, including stem and progenitor cells (HSPCs), and it plays a critical role in the differentiation of naïve CD4? T-cells into different T helper subsets . In humans, mutations in the extracellular domain of CD40L give rise to a rare immunodeficiency disorder, the X-linked hyper-IgM syndrome, characterized by increased susceptibility to infections and defective Ig isotype switching, resulting in low or undetectable serum levels of IgG and IgA, and normal or elevated IgM (Aruffo et al. 1993) .
Besides its expression in activated CD4? T cells, CD40L is also found in a broad range of cells including T cells, B cells, basophils, eosinophils, NK cells, macrophages, dendritic cells, and endothelial cells (Mach et al. 1997; Schonbeck et al. 2000) . Moreover, CD40L is constitutively expressed in megakaryocytes, and activated platelets appear to be the primary source of plasma sCD40L (Henn et al. 1998; Inwald et al. 2003) . Emerging evidences suggest that platelet CD40L is involved in the adaptive immune response (Elzey et al. 2011) and, also, it may contribute to inflammatory diseases, including atherosclerosis (Nurden 2011; Hassan et al. 2012) . Moreover, platelet CD40L has been reported to stabilize arterial thrombi through a mechanism involving interaction with aIIbb3 integrin (Andre et al. 2002b) . Many of these studies were performed using a total CD40L knockout mouse model (Xu et al. 1994) , the only CD40L-deficient mice so far reported.
In this work, we intended to study the role of CD40L in different cell types. For this purpose, we have crossed a CD40L ''floxed'' mouse line (Nowakowski et al. 2011 ) with four different transgenic mice with restricted expression of Cre recombinase in the hematopoietic system, driven by Tie2 (the gene for tunica intima endothelial kinase 2), Vav1 (coding for a guanine nucleotide exchange factor), CD4 (cluster of differentiation 4), and Pf4 (coding for the platelet factor 4) promoters. These lines were selected because they express Cre recombinase at different developmental stages, therefore offering additional information on the possibility that CD40L-dependent developmental events could influence the functional response. Evaluation of in vivo thrombogenesis and CD40L-deficient platelet activation, as well as determination of serum Ig levels in mice carrying CD40L-deficient leukocytes, provide valuable data on the functional significance of CD40L expression.
Materials and methods

Ethics statement
All experiments with animals were done in such a way as to minimize animal suffering, according to relevant national and international guidelines (''Guide for Care and Use of Laboratory at the Institute of Laboratory Animal Resources'').
The ethics committee of the Center for Biological Research (CSIC) and the grant review board (ANEP) of the Spanish Ministry of Science and Technology specifically approved this study in accordance with the guidelines of the European Community Council Directive 86/609 EEC.
Animals
Mice used in all the experiments were maintained under controlled conditions of light and temperature. Cd40lg f/f ::Pf4-Cre, Cd40lg f/f ::Vav-Cre, and Cd40lg f/f ::CD4-Cre littermates were generated on a mixed C57BL/6-129sv, and CD40L f/f ::Tie2-Cre on a mixed CD1 genetic background, and were backcrossed for 10 generations with C57BL/6 or CD1 mice, respectively.
To generate mice with a restricted deletion of Cd40lg in endothelial and/or hematopoietic cells, mice homozygous for the floxed allele (with exons 3-4 flanked by functional loxP sites) generated previously (Nowakowski et al. 2011 ) were crossed to Pf4-Cre mice (generated and kindly gifted by Dr. R.C. Skoda, University Hospital Basel, Switzerland) (Tiedt et al. 2007 ), Tie2-Cre mice (kindly gifted by Dr. J.L. de la Pompa, National Centre of Biotechnology, Madrid, Spain) (Kisanuki et al. 2001 (Lee et al. 2001) .
PCR genotyping
Recombination of the Cd40lg gene region flanked by the loxP sequences was verified by PCR analysis of genomic DNA. Oligonucleotides loxP-S: 5 0 -TTTCAC TCCAGGTGATGAGG-3 0 (overlapping intron3-exon4 sequences) and AS-8774: 5 0 -AATCTAACGTCTCAG CGCCTAT-3 0 that targets a sequence in intron 4 were used to verify the correct insertion of the right loxP sequence in ''floxed'' mice. The same antisense primer and S-5669: 5 0 -ATAAGCACCCACAAAACACAC T-3 0 located in intron 2 were used to confirm the deletion of a DNA fragment comprising exons 3 and 4 in genomic DNA from endothelial cells of Tie2-Cre? and leukocytes of Vav1-and CD4-Cre? mice. Deletion of exons 3-4 in genomic DNA from in vitro differentiated megakaryocytes was verified with oligonucleotides S-5669 and AS-9514: 5 0 -GTTAGGTC AATCTCTGGTTATCAC-3 0 located in intron 4. For littermate genotyping, tail genomic DNA and oligonucleotides S-6012: 5 0 -CCAGGGATTCCCAAT TGCTAT-3 0 and AS-6259: 5 0 -CAAAATTGGTAATA GCAACCTACC-3 0 were used to verify amplification of a DNA fragment comprising the left loxP sequence, and identification of Cre? mice was performed by amplification of a DNA fragment with a sense oligonucleotide targeting a sequence of the specific promoter and an antisense primer targeting the Cre gene sequence.
RT-PCR analysis of CD40L expression
Total RNA from in vitro differentiated mouse megakaryocytes, platelets, peripheral blood mononuclear cells (PBMCs), and CD4
? T cells, and from mouse and human endothelial cells, was obtained using the ''High Pure RNA Isolation Kit'' from Roche. After removing platelet-rich plasma, peripheral blood was layered onto Histopaque 1083 (Sigma) or LymphoPrep (Progen Biotechnik) for separation of mouse or human PBMCs, respectively. A magnetic bead-based kit from Miltenyi was used to isolate mouse CD4? T cells from total blood previously treated with hypotonic buffer to lyse red cells.
RT-PCR amplification with oligonucleotides S-ATG: 5 0 -GCATGATAGAAACATACAG-3 0 located in exon 1 and AS-TGA: 5 0 -TGTTCAGAGTTTGAGT AAGCC-3 0 located in exon 5 confirmed normal sized cDNA in in vitro differentiated megakaryocytes from floxed mice and the deletion of exons 2-3 in cells from Cre? mice.
Oligonucleotide pairs with a common antisense primer (AS-TGA) and sense primers S-WT: 5 0 -TGCA AAAAGGTGATCAGAATC-3 0 overlapping exons 3 and 4, S-KO: 5 0 -GAAGACCTTGTCAAGTTCTACA-3 0 overlapping exons 2 and 5, and S-Sp: 5 0 -CTTGTCA AGGTGATGAGGA-3 0 overlapping exons 2 and 4, were designed to amplify similarly sized products corresponding to the normal, exons-2-3-deleted, and exon-3-deleted transcripts, respectively.
RT-PCR analysis was also performed in human platelets, PBMCs, umbilical vein endothelial cells (HUVEC), human microvascular endothelial cell line (HMEC-1), and blood outgrowth endothelial cells established from peripheral blood (BOEC), using the same AS-TGA primer, conserved in the human sequence, and sense primers S-hWT: 5 0 -TGCAAAA AGGTGATCAGAATC-3 0 overlapping exons 3 and 4, and S-hSp: 5 0 -GGCTTTGTGAAGGTGATCA-3 0 overlapping exons 2 and 4, to amplify similarly-sized products corresponding to the normal and exon-3-deleted transcripts, respectively.
In all RT-PCR assays, amplification of a cDNA fragment of human or mouse b-actin was carried out in parallel to verify that equal amounts of RNA were used ensuring correct normalization of CD40L expression.
All RT-PCR assays were carried out twice, with similar results, using two different mixtures of RNA from at least 3 animal of each genotype.
In vitro differentiation of megakaryocytes
Bone marrow cells were flushed from femurs and tibias with Tyrode's buffer, dissociated and cultured in IMDM with 5 % fetal bovine serum, 50 ng/mL TPO, 2 mM L-glutamine, 50 U/mL penicillin, and 50 lg/mL streptomycin. Megakaryocytes were recovered by passing the suspension through a discontinuous density gradient of albumin.
Endothelial cell isolation and culture Mice lungs from Cd40lg lox/lox and Cd40lg -/-littermates were collected, chopped, digested with 1 mg/mL collagenase A (Roche, 10103578001), filtered through a sterile 18G microlance, and sieved through a cell strainer with 70 lm nylon membrane pore (Beckton and Dickinson). The purification of endothelial cells was carried out by a single negative sorting with anti-CD16/32 antibody (BD Pharmigen, 553142) and a single positive sorting with anti-ICAM2 antibody (BD Pharmigen, 553326), using Dynabeads sheep anti-rat IgG (Invitrogen, 110.35) and a magnetic particle concentrator (Dynamag TM -15, Invitrogen 123.01D). Endothelial cells were plated on gelatincoated 60 mm dishes and cultured during 3 days in medium containing DMEM (Gibco, 41966), Hams F-12 (Lonza, BE12-615F), 100 UI/mL penicillin/ 100 lg/mL streptomycin (Gibco, 15070-063), 20 % fetal bovine serum (Sigma F7520), 20 lg/mL endothelial cell growth supplement from bovine neural tissue (ECGS, Sigma E2759) and 0.1 mg/mL of heparin sodium salt (Sigma, H3393). Finally, trypsin-detached cells were labeled with anti-ICAM2-FITC antibody (BD Pharmigen, 557444) and analyzed in a Coulter flow cytometer model EPICS XL. Only cultures with percentages greater that 90 % of endothelial cells were used.
Flow cytometry analysis of surface expression of CD40L
Cell suspensions from mouse spleens were prepared by mechanical dissociation. Debris was removed by sedimentation followed by filtration through a 70 lm cell strainer, centrifugation, and resuspension in DMEM-10 % FCS. After cell counting, single-cell suspensions from three animals of each genotype were mixed for cell activation assays. Spleen single-cell suspension (10 7 cells) were incubated in the absence or presence of 50 ng/mL PMA and 1 lg/mL ionomycin and, then, washed and stained with anti-CD40L(clon MR1)-PE and anti-CD4(clon GK1.5)-FITC (eBioscience) or isotype-matched antibodies as negative control for 15 min at 4°C, washed, and analyzed in a Coulter flow cytometer model FC500. The experiment was carried out twice with similar results.
Preparation and activation of washed platelets
Citrated blood samples were obtained by cardiac puncture under isofluorane anesthesia. The blood was centrifuged at 100 g for 20 min at room temperature. Platelet-rich plasma (PRP) was removed and centrifuged at 1,300g in the presence of 0.1 lg/mL prostacyclin and 0.02 U/mL apyrase (Sigma) for 5 min at room temperature, and washed 3 times with modified Tyrode's buffer containing 0.1 lg/mL prostacyclin and 0.02 U/mL apyrase. The sedimented platelets were finally suspended in Tyrode's buffer containing 0.02 U/mL apyrase and rested for 30 min at 37°C prior to stimulation.
The membrane content of surface receptors was determined in washed platelets incubated with FITClabeled rat anti-mouse integrin aIIbb3 and GPVI (Emfret Analytics, Eibelstadt, Germany) or control isotype-matched mouse IgGs for 30 min at room temperature. The samples were then washed and analyzed by flow cytometry.
To determine the extent of platelets activation, 25 lL of washed platelets (10 6 approximately) suspended in Tyrode's-buffer containing 1 mM CaCl 2 were stimulated with 10 lM ADP plus 50 lM epinephrine, or 0.2-1 U/mL thrombin. Activation was assessed by determining P-selectin exposure and aIIbb3 activation by flow cytometry with 5 lL of FITC-anti-P-selectin (Beckton and Dickinson) or PE-anti-activated aIIbb3 (JON/A, Emfret Analytics) moAbs.
Thrombogenesis in vivo
As previously reported (Pericacho et al. 2011) , 100 lL of blood was collected from one of the jugular veins of anesthetized mice into a tube containing 10 lL of 0.129 M sodium citrate. A mixture of collagen/epinephrine (150 ng collagen type I (Chronolog) and 15 ng epinephrine (SIGMA) per g of mice body weight) was then injected into the same vein and, after 2 min, blood was withdrawn from the other jugular vein as indicated above. The number of platelets in both samples was determined using a hemocytometer analyzer Abacus Junior (Diatron Messtechnik GmbH, Austria).
Immunoglobulin measurement by flow cytometry
Immunoglobulin detection in ''floxed'' and conditional knockout mice from VAV-Cre, Tie2-Cre and CD4-Cre lines was performed with the Mouse Immunoglobulin Isotyping panel 6plex kit (eBioscience, BMS815FF) by flow cytometry, following manufacturer's instructions. Non-citrated blood was extracted by cardiac puncture of 12-week-old mice. Complete blood was stored overnight at 4°C and, after centrifugation at maximum speed, serum was collected and used to detect IgA, IgG1, IgG2a, IgG2b, IgG3 and IgM immunoglobulins. Results obtained were analyzed with FlowCytomix Pro Software (eBioscience) to determine immunoglobulin concentration.
Results
CD40L expression in mouse lines with conditional knockout of CD40L in hematopoietic cells
To study the functional consequences of conditional knockout of CD40L, mice bearing two copies of the Cd40lg floxed allele generated as previously described (Nowakowski et al. 2011) (Fig. 1a) were mated with transgenic mouse lines expressing Cre recombinase driven by the promoters of three different genes that are expressed in T cells: Tie2 (the gene for tunica intima endothelial kinase 2), Vav1 (coding for a guanine nucleotide exchange factor), and CD4 (cluster of differentiation 4). The Tie2-Cre line (Kisanuki et al. 2001) produces Cre recombinase in endothelial cells and their progeny, including hematopoietic stem cells (HSC) and blood cells (Hsu et al. 2000) ; the Vav-iCre line (de Boer et al. 2003 ) expresses the Cre recombinase specifically in hematopoietic cells but only after HSC formation (He et al. 2008) ; and the CD4-Cre line allows the Cre-recombinase to act on a later step of T cell development, the CD4? T cells (Lee et al. 2001) , and also in an early step in megakaryocyte maturation (Basch et al. 1996) . Using genomic DNA from endothelial cells and leukocytes, we verified the correct insertion of right loxP sequence in ''floxed'' mice and the deletion of a DNA fragment comprising exons 3 and 4 in Cre? mice (Fig. 1b, c) .
We assessed CD40L expression by RT-PCR analysis of the CD40L transcripts. We designed oligonucleotide pairs consisting of a common antisense primer located in exon 5 and specific sense primers to amplify the normal or the deleted transcript. As shown in Fig. 2 , in the three mouse lines, amplification of the normal transcript using a sense primer overlapping exons 2 and 3 was detected in platelets and leukocytes from control ''floxed'' mice, but not from Cre? mice. In contrast, amplification with a sense primer overlapping exons 2 and 5 allowed detection of the deleted transcript only in Cre? mice. Ablation of the Cd40lg gene in all these animals has not apparent effect on phenotype. The rates of growth and fertility were normal and no significant differences were detected in hemogram counts (Table S1) .
In order to demonstrate the absence of CD40L protein in targeted cells, spleen cell suspensions from ''floxed'' and Cre? mice were stimulated with PMA/ ionomycin and the surface expression of CD40L was determined in CD4? cells by flow cytometry. As shown in Fig. 3 , for all three Cre lines, CD40L was clearly detected in ''floxed'' mice but not in Cre? mice.
We also generated a fourth mouse line by mating Cd40lg f/f mice with mice expressing Cre-recombinase under the control of platelet factor 4 promoter (Pf4) (Tiedt et al. 2007) . In contrast to the other mouse lines, the results from semiquantitative RT-PCR analysis in platelets revealed an inefficient Cre-mediated recombination. As shown in Fig. 4a , the deleted transcript was detected in Cre? mice only after 40 cycles of PCR amplification. Consistent with the scarce amount of the mutant transcript, amounts of amplification products of the normal transcript were similar to those obtained in ''floxed'' mice. However, efficient Cremediated excision of the floxed allele was demonstrated in in vitro cultured megakaryocytes. We verified the deletion of a DNA fragment comprising exons 3 and 4 in Cre? mice (Fig. 1d) . Moreover, amplification with oligonucleotides located in exons 1 and 5 yielded a cDNA product corresponding to the normal transcript in megakaryocytes from ''floxed'' mice and a product corresponding to the transcript with deletion of exons 3-4 in cells from Cre? mice (Fig. 4b) .
Expression of an exon 3-deleted transcript of CD40L in both platelets and leukocytes During sequence analysis of RT-PCR products we detected an alternative form of CD40L transcript lacking exon 3 in platelets from mice bearing the Cd40lg floxed allele. In order to rule out the possibility of aberrant splicing caused by the presence of the 5 0 -loxP site, introduced 48 bp upstream of exon 3, we designed a sense primer overlapping exons 2 and 4 and analyzed by RT-PCR the relative expression of this alternative transcript. Results in Fig. 5a show that the exon 3-deleted CD40L transcript is present in both platelets and leukocytes from wild type mice of the same genetic backgrounds. In addition, it was also found in platelets and leukocytes of human origin (Fig. 5b) . When compared with expression of the full-length transcript, we estimated that it represents a minor proportion (\5 %) of total CD40L transcripts (Fig. 5) . Skipping of exon 3 results in frameshift and premature stop codon 36 bp downstream. Thus, the aberrant transcript is predicted to encode a protein carrying an abnormal and severily truncated amino acid composition at the extracellular aminoterminal region.
CD40L expression in mouse and human endothelial cells
Early reports on CD40L expression have led to the general consent that CD40L is expressed in endothelial cells, at least of human origin (Mach et al. 1997; Schonbeck et al. 2000) . In the present study, RT-PCR of total RNA from mouse lung vascular endothelial cells (MLEC) revealed that CD40L expression is not detectable after 45 cycles of amplification (Fig. 6a) . We also failed to detect CD40L in total RNA from human umbilical vascular endothelial cells (HUVEC) and human blood outgrowth endothelial cells (BOEC) (Fig. 6b) . It was only detectable, although scarcely when compared with its expression in leukocytes and platelets, in RNA from human dermal microvascular endothelial cells (HMEC-1) (Fig. 6b) . and Cre? mice (lane 3) was used for RT-PCR amplification of the wild type and deleted transcripts of CD40L, using a common antisense primer and specific sense primers, as described in ''Materials and methods''. b Total RNA from bone marrow cells differentiated to megakaryocytes was used for RT-PCR amplification of CD40L using sense and antisense primers located in exons 1 and 5, respectively, as described under ''Materials and methods''. The experiments were performed twice with similar results Fig. 5 Detection of an exon 3-deleted transcript in platelets and leukocytes of mouse and human origin. Total RNA from platelets and PBMCs of mouse (a) and human (b) was used for RT-PCR amplification of cDNA fragments of CD40L corresponding to the full-length and exon 3-deleted transcripts, using a common antisense primer and specific sense primers as described under ''Materials and methods''. The experiments were performed twice with similar results
In vivo thrombogenesis and in vitro platelet activation in CD40L knockout mice Studies carried out with the Cd40lg -/-mouse model (Xu et al. 1994) show a normal hemostasis. However, alteration in thrombus formation (Andre et al. 2002a) has been reported indicating a role of CD40L in protection against thrombosis. Platelets seem to be the main source of sCD40L and a decrease in the concentration of sCD40L inside the thrombus has been related with the thrombogenic defect of the Cd40lg -/-mice (Prasad et al. 2003) . We performed in vivo thrombogenesis experiments by inducing pulmonary thromboembolism by intravenous administration of collagen plus epinephrine. Results summarized in Fig. 7 indicate that Vav-iCre? mice display a significantly smaller decrease in circulating platelets 2 min after the administration of agonists than Vav-iCre-animals, indicating that CD40L-deficient mice have a decreased thromboembolic response. However, no significant differences were observed in Tie2-Cre? and CD4-Cre? mice.
A role for CD40L in fibrin clot formation can be excluded in view that Cre? mice of the three lines showed similar values of prothrombin time (PT) and activated partial thromboplastin time (aPTT) than their littermate ''floxed'' controls (Table S2) .
Washed CD40L-deficient platelets obtained from the three mouse lines under study show a significant decrease of aIIbb3 activation in response to thrombin, as determined by the binding of JON/A antibody that selectively binds to the high affinity conformation of mouse aIIbb3 (Fig. 8a) . Although platelet activation in response to ADP/epinephrine was also reduced in all Cre? mice, the effect was statistically significant only in platelets from Vav-Cre? mice. These mice also showed reduced P-selectin release after thrombin stimulation (Fig. 8b) . These effects were not due to decreased surface expression of aIIbb3 and GPVI receptors (Table S3) .
Serum immunoglobulin levels in CD40L deficient mice
One of the characteristic features of X-linked hyper IgM syndrome is the alteration in the serum immunoglobulin phenotype (Aruffo et al. 1993) . Serum from Fig. 7 Relative fall in circulating platelets induced by the i.v. administration of collagen/epinephrine. Blood was collected from the jugular vein followed by i.v. injection of a mixture of collagen and epinephrine and, after two minutes, blood was withdrawn from the contralateral vein and the platelet count in both samples determined using a hemocytometer as described in ''Materials and methods''. The data represent the percent of reduction in the number of circulating platelets and are mean values ± SEM of at least 6 animals. The Anderson-Darling test was used to verify normal distribution of data. The significance of the results was assessed by two tailed, unpaired, t test. ns non significant Transgenic Res (2014) 23:53-66 61 patients contains elevated levels of IgM, and low to undetectable levels of other immunoglobulin isotypes, including IgG. To determine whether CD40L deficiency associates in mice with a similar phenotype, we determined the immunoglobulin levels in serum from eight control ''floxed'' and eight Cre? mice of each Cre line. Table 1 shows that the alterations in the serum levels of Igs varied in the different mouse lines. 
Discussion
At present, the only available mouse line deficient for CD40L is a total knockout model generated by replacing a 506-bp DNA fragment containing part of exon 4 with the pCM1 gene in an opposite direction (Xu et al. 1994 ). These mice have been used to explore the role of CD40-CD40L interaction on different aspects of the immune response as well as on atherogenic and inflammatory processes (Wolf et al. 2012; Lievens et al. 2010) .
We have recently generated a Cd40lg ''floxed'' mouse line in which Cd40lg alleles carry loxP sites flanking a DNA fragment comprising exons 3-4 (Nowakowski et al. 2011) . In the present study, we have crossed these animals with three different Cre mouse lines (Tie2-Cre, Vav-iCre, and CD4-Cre) in order to explore the effect of restricting expression of CD40L at different steps of hematopoietic development. Efficiency of Cre-mediated ablation of Cd40lg in lymphocytes and platelets was assessed by RT-PCR analysis of CD40L transcripts. The normal transcript was not found in Cre? mice, indicating efficient Cremediated recombination. Although we have not performed a precise quantitative determination of the CD40L-mRNA levels, the semiquantitative RT-PCR analysis indicates that the amounts of normal and deleted transcripts detected in cells from ''floxed'' and Cre? mice, respectively, were similar. The mutant transcript is predicted to produce a protein carrying an abnormal and severely truncated extracellular region lacking the CD40 receptor-binding domain. A similarly truncated CD40L protein has been described previously in a patient causing X-linked hyper IgM syndrome through a dominant negative inhibition of CD40L trimeric complex formation (Zhu et al. 2001) . Although, given the relatively high expression of the deleted transcript in our Cre? mice, we cannot exclude that these animals express significant amounts of a dysfunctional CD40L protein, the flow cytometry analysis of CD4? T cells stimulated with PMA/ ionomycin indicates that CD40L is practically absent in cells from Cre? mice.
The role of platelet CD40L in thrombosis (Inwald et al. 2003; Prasad et al. 2003) and, also, its emerging function in both innate and adaptive immunity (Semple et al. 2011; Li et al. 2012) , inflammation (Nurden 2011; Wolf et al. 2012) , and atherosclerosis (Elzey et al. 2011; Wolf et al. 2012; Lievens et al. 2010; Semple et al. 2011; Li et al. 2012) prompted us to develop a mouse line with megakaryocytic specific ablation of CD40L, by using Pf4-Cre mice. Although the floxed Cd40lg allele was efficiently excised in in vitro differentiated megakaryocytes from Pf4-Cre? mice, we found that circulating platelets from control ''floxed'' and Cre? mice carry similar amounts of the CD40L normal transcript, suggesting a practically total failure of Cre to induce recombination in vivo. Other genes expressed in megakaryocyte/platelet, like b1 integrin or podocalyxin, have been successfully excised using the same Pf4-Cre transgenic mouse line (Tiedt et al. 2007; Pericacho et al. 2011) , which discards a deficient expression of Cre recombinase. Persistence of a Cre-recombination episomal product has been reported to be the cause of absolute lack of protein loss in an inducible Cre mouse model where efficient DNA deletion occurred (Turlo et al. 2010 ). This possibility is unlikely in our case; although we have not confirmed that loxP alleles were not appropriately targeted during in vivo differentiation of megakaryocytes, the almost undetectable levels of deleted transcripts in platelets (Fig. 4a) , compared with those obtained in the other Cre mouse lines (Fig. 2a-c) , points to a deficient Cre-mediated excision. Thus, these results indicate that, for unexplained reasons, Pf4-driven Cre expression fails to excise this Cd40lg floxed allele during in vivo differentiation of megakaryocytes, and highlight the need of validate protein depletion in vivo for every novel Cre/loxP combination.
The decreased pulmonary thrombogenic response observed in vivo in Vav-iCre? mice supports the role of CD40L in thrombus formation and/or stability. This role has been claimed to be mediated by sCD40L in humans. Several pathologies involving thrombotic risk (hypercholesterolaemia, diabetes, stroke or acute coronary syndromes) show platelet activation and high levels of sCD40L (Tousoulis et al. 2010; Nurden 2011) . We show that activation of aIIbb3 in response to thrombin was significantly reduced in washed platelets from the three Cre mouse lines. This effect was more pronounced in Vav-iCre? mice, which also showed deficient integrin activation upon ADP/epinephrine stimulation, reduced P-selectin exposure in response to thrombin, and a diminished thrombogenic response in vivo. These effects were not due to defective expression of aIIbb3. Previous studies addressing the function of platelet CD40L have shown that the absence of CD40L impairs thrombus stability and delays arterial occlusion in vivo (Andre et al. 2002b; Prasad et al. 2003) . However, isolated platelets stimulated with soluble CD40L (sCD40L) have yielded somewhat differing conclusions on CD40L-mediated platelet activation. Addition of sCD40L to platelets has been shown to promote CD40-mediated exposure of P-selectin and granule release, but not platelet aggregation (Inwald et al. 2003) . By contrast, activation of aIIbb3 and platelet aggregation under high shear, mediated by the binding of sCD40L to aIIbb3, has been reported after addition of sCD40L to CD40-deficient platelets (Andre et al. 2002b; Prasad et al. 2003) . Our experiments showing defective activation of washed CD40L-deficient platelets add further insights into the functional significance of platelet CD40L and suggest that membrane-bound CD40L is involved in the control of hemostasis acting as a platelet co-activator.
In humans, mutations in the Cd40lg gene cause X-linked hyper IgM (X-HIGM) immunodeficiency syndrome, characterized by recurrent infections, low levels of serum IgG, IgA and IgE, and elevated or normal levels of serum IgM due to defective immunoglobulin isotype switching (Levy et al. 1997) . Consistent with a previous study carried out in a total knockout mouse model (Xu et al. 1994) , conditional knockout of the Cd40lg gene did not associate to increased levels of serum IgM in any of the three mouse lines expressing Cre in hematopoietic cells. By contrast, IgM levels were significantly reduced in Tie2-Cre? and Vav-iCre? mice. In consonance with these data, a recent report has revealed that about 50 % of X-HIGM patients do not present increased IgM and in approximately 6.4 % of the cases the IgM levels are decreased, suggesting that patients with total hypogammaglobulinemia may not have undergone diagnostic procedures for X-HIGM and detection of Cd40lg mutations (Heinold et al. 2010) . Determination of serum levels of IgA and IgG subclasses also yielded unexpected results. Vav-iCre? and CD4-Cre? mice showed no significant changes, and the decrease detected in Tie2-Cre? mice, although significant, may not be sufficient to have functional relevance. It is known that CD40L is involved in haematopoietic development, including stem and progenitor cells (HSPCs), T cell, B-cell, and dendritic cell progenitors, and it plays a critical role in the differentiation of naïve CD4? T-cells into different T helper subsets . Expression of CD40L in one of these subpopulations, the T follicular helper cells, is thought to be essential to mediate antibody class switching through the interaction with its receptor, CD40, in mature B cells (Aversa et al. 1994) . Our study shows that abolishing expression of CD40L at different steps of hematopoietic cell development does not seem to have a significant impact on class switch recombination suggesting that, at least in mouse, expression of CD40L in an earlier stage of development may be determinant in the regulation of this process. The significant decrease of IgA and IgG in mice expressing Cre under the Tie2 promoter, activated earlier than Vav1 and CD4 promoters during development, supports this possibility. Alternatively, as observed in an increasing number of mouse models (Montagutelli 2000; Jelcick et al. 2011) , it may reflect the difference between C57BL/6-129sv and CD1 genetic backgrounds. Finally, even in case the deleted CD40L transcript expressed in Cre? mice was translated into a protein, the absence of CD40 binding-domain would preclude its functionality to induce class switch recombination.
Finally, it is worthy to mention that, in contrast to previous reports (Mach et al. 1997; Wagner et al. 2004) , we have failed to detect CD40L expression in mouse and human endothelial cells. Scarce RNA expression was only found in a human microvascular endothelial cell line (HMEC-1). Although CD40L expression could be upregulated in inflammatory contexts (Reul et al. 1997; Geraldes et al. 2006) , our results suggest that endothelial CD40L has not functional relevance in basal conditions. In summary, we have established three novel mouse lines with conditional knockout of the Cd40lg gene in the hematopoietic system and verified the efficient Cre-mediated deletion of CD40L in targeted cells. In contrast, ablation of Cd40lg was only observed in in vitro differentiated megakaryocytes in a fourth mouse model with Cre expression restricted to the megakaryocyte lineage. Mice carrying CD40L-deficient leukocytes do not exhibit increased levels of serum IgM, and reduction of IgA and IgG levels was statistically significant only in Tie2-Cre? mice. Our results also show defective activation of washed CD40L-deficient platelets and reduced in vivo thrombogenesis, adding further insights into the functional significance of platelet CD40L. Finally, we report the practically absence of CD40L in mouse and human endothelial cells and, also, the detection of an exon 3-deleted CD40L transcript in both platelets and leukocytes of mouse and human origin.
